Browse GLYAT

Summary
SymbolGLYAT
Nameglycine-N-acyltransferase
Aliases GAT; ACGNAT; AAc; HRP-1(CLP); acyl-CoA:glycine N-acyltransferase; aralkyl acyl-CoA N-acyltransferase; aralky ......
Chromosomal Location11q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Mitochondrion
Domain PF08444 Aralkyl acyl-CoA
PF06021 Aralkyl acyl-CoA
Function

Mitochondrial acyltransferase which transfers an acyl group to the N-terminus of glycine and glutamine, although much less efficiently. Can conjugate numerous substrates to form a variety of N-acylglycines, with a preference for benzoyl-CoA over phenylacetyl-CoA as acyl donors. Thereby detoxify xenobiotics, such as benzoic acid or salicylic acid, and endogenous organic acids, such as isovaleric acid.

> Gene Ontology
 
Biological Process GO:0006520 cellular amino acid metabolic process
GO:0006544 glycine metabolic process
GO:0006637 acyl-CoA metabolic process
GO:0006732 coenzyme metabolic process
GO:0006790 sulfur compound metabolic process
GO:0006805 xenobiotic metabolic process
GO:0009069 serine family amino acid metabolic process
GO:0009410 response to xenobiotic stimulus
GO:0009636 response to toxic substance
GO:0035383 thioester metabolic process
GO:0051186 cofactor metabolic process
GO:0071466 cellular response to xenobiotic stimulus
GO:1901605 alpha-amino acid metabolic process
Molecular Function GO:0016410 N-acyltransferase activity
GO:0016746 transferase activity, transferring acyl groups
GO:0016747 transferase activity, transferring acyl groups other than amino-acyl groups
GO:0047961 glycine N-acyltransferase activity
GO:0047962 glycine N-benzoyltransferase activity
Cellular Component GO:0005759 mitochondrial matrix
> KEGG and Reactome Pathway
 
KEGG hsa00360 Phenylalanine metabolism
Reactome R-HSA-156587: Amino Acid conjugation
R-HSA-211859: Biological oxidations
R-HSA-177135: Conjugation of benzoate with glycine
R-HSA-159424: Conjugation of carboxylic acids
R-HSA-177128: Conjugation of salicylate with glycine
R-HSA-1430728: Metabolism
R-HSA-156580: Phase II conjugation
Summary
SymbolGLYAT
Nameglycine-N-acyltransferase
Aliases GAT; ACGNAT; AAc; HRP-1(CLP); acyl-CoA:glycine N-acyltransferase; aralkyl acyl-CoA N-acyltransferase; aralky ......
Chromosomal Location11q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GLYAT and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolGLYAT
Nameglycine-N-acyltransferase
Aliases GAT; ACGNAT; AAc; HRP-1(CLP); acyl-CoA:glycine N-acyltransferase; aralkyl acyl-CoA N-acyltransferase; aralky ......
Chromosomal Location11q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GLYAT in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolGLYAT
Nameglycine-N-acyltransferase
Aliases GAT; ACGNAT; AAc; HRP-1(CLP); acyl-CoA:glycine N-acyltransferase; aralkyl acyl-CoA N-acyltransferase; aralky ......
Chromosomal Location11q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GLYAT in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.5020.313
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0390.962
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.9090.221
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9161.1850.151
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.9020.478
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.5320.268
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.570.595
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.3160.473
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-2.8480.117
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2390.921
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7350.818
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.920.00388
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GLYAT in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.74.1-0.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.75.1-1.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolGLYAT
Nameglycine-N-acyltransferase
Aliases GAT; ACGNAT; AAc; HRP-1(CLP); acyl-CoA:glycine N-acyltransferase; aralkyl acyl-CoA N-acyltransferase; aralky ......
Chromosomal Location11q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GLYAT. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGLYAT
Nameglycine-N-acyltransferase
Aliases GAT; ACGNAT; AAc; HRP-1(CLP); acyl-CoA:glycine N-acyltransferase; aralkyl acyl-CoA N-acyltransferase; aralky ......
Chromosomal Location11q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GLYAT. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GLYAT.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGLYAT
Nameglycine-N-acyltransferase
Aliases GAT; ACGNAT; AAc; HRP-1(CLP); acyl-CoA:glycine N-acyltransferase; aralkyl acyl-CoA N-acyltransferase; aralky ......
Chromosomal Location11q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GLYAT. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGLYAT
Nameglycine-N-acyltransferase
Aliases GAT; ACGNAT; AAc; HRP-1(CLP); acyl-CoA:glycine N-acyltransferase; aralkyl acyl-CoA N-acyltransferase; aralky ......
Chromosomal Location11q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GLYAT expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGLYAT
Nameglycine-N-acyltransferase
Aliases GAT; ACGNAT; AAc; HRP-1(CLP); acyl-CoA:glycine N-acyltransferase; aralkyl acyl-CoA N-acyltransferase; aralky ......
Chromosomal Location11q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GLYAT and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGLYAT
Nameglycine-N-acyltransferase
Aliases GAT; ACGNAT; AAc; HRP-1(CLP); acyl-CoA:glycine N-acyltransferase; aralkyl acyl-CoA N-acyltransferase; aralky ......
Chromosomal Location11q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GLYAT collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting GLYAT.
ID Name Drug Type Targets #Targets
DB00145GlycineSmall MoleculeAGXT, AGXT2, ALAS1, ALAS2, BAAT, GARS, GATM, GCAT, GCSH, GLDC, GLR ......30